GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (NAS:KA) » Definitions » Financial Strength

Kineta (Kineta) Financial Strength : 4 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Kineta Financial Strength?

Kineta has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Kineta did not have earnings to cover the interest expense. As of today, Kineta's Altman Z-Score is -26.09.


Competitive Comparison of Kineta's Financial Strength

For the Biotechnology subindustry, Kineta's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kineta's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Financial Strength distribution charts can be found below:

* The bar in red indicates where Kineta's Financial Strength falls into.



Kineta Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Kineta's Interest Expense for the months ended in Dec. 2023 was $-0.27 Mil. Its Operating Income for the months ended in Dec. 2023 was $-4.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.15 Mil.

Kineta's Interest Coverage for the quarter that ended in Dec. 2023 is

Kineta did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Kineta's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.167 + 0.15) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Kineta has a Z-score of -26.09, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -26.09 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kineta  (NAS:KA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Kineta has the Financial Strength Rank of 4.


Kineta Financial Strength Related Terms

Thank you for viewing the detailed overview of Kineta's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Kineta (Kineta) Business Description

Traded in Other Exchanges
Address
219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.
Executives
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky director C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust 10 percent owner C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust 10 percent owner C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109